Naveed Shams is a prominent inventor based in Emeryville, CA (US), known for his significant contributions to the field of pharmaceuticals. With a total of 10 patents to his name, he has focused on developing innovative treatments for glaucoma and ocular hypertension.

Latest Patents

His latest patents include a pharmaceutical formulation comprising a pyridylaminoacetic acid compound. This preparation is designed for the treatment or prevention of glaucoma or ocular hypertension, containing specific concentrations of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof. Another notable patent involves a pharmaceutical preparation that aims to treat or prevent glaucoma or ocular hypertension, particularly for patients who have not responded adequately to existing therapeutic agents. This invention highlights the efficacy of omidenepag, an ester or salt thereof, in lowering intraocular pressure in such patients.

Career Highlights

Naveed Shams has made remarkable strides in his career, particularly through his work at Santen Pharmaceutical Co., Ltd. His research and innovations have positioned him as a key figure in the development of effective glaucoma treatments.

Collaborations

He has collaborated with notable colleagues, including Hisashi Kawata and Noriko Kawabata, to advance his research and patent applications.

Conclusion

Naveed Shams continues to be a driving force in pharmaceutical innovation, particularly in the treatment of glaucoma and ocular hypertension. His contributions are paving the way for more effective therapies in this critical area of healthcare.

This text is generated by artificial intelligence and may not be accurate.